Basel Medical raises $7.98M in registered direct offering on Nasdaq
What's the deal? Basel Medical GroupDealroom has a profile for this one. Try Dealroom → (Nasdaq: BMGL) has priced a registered direct offering for $7.98 million in gross proceeds, the Singapore-based company said on October 8. It will issue 6,000,000 units at $1.33 each, with Cathay SecuritiesDealroom has a profile for this one. Try Dealroom → acting as placement agent.
The details: Each unit pairs one ordinary share — or a pre-funded warrant — with one common warrant to buy an additional share. Net proceeds are estimated at roughly $7.28 million after commissions and expenses.
How the warrants work: The common warrants are exercisable immediately at 110% of the offering price and expire in five years. They carry a zero-cash exercise option, meaning the company likely will not collect additional funds from them.
Why now? Basel MedicalDealroom has a profile for this one. Try Dealroom → held just 1,582,111 ordinary shares outstanding before the deal, making this a sizeable expansion of its share base. The offering is registered under an effective Form F-1, so the shares will be freely tradeable once the deal closes.
The signal: At $7.98 million, this is a modest raise — it sits in roughly the bottom 9% of funding rounds by size. For a small-cap Nasdaq company, the registered direct structure offers a fast route to capital, trading dilution for speed.
Read more: marketscreener.com
Image credit: Generated with Gemini
